Physician profile
John W Grimes
NPI 1174956908
$5,992.58
in general payments reported to CMS, 2019-2025
17 companies · $2,255 in 2025
The $2,255 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $577 · 2022: $622 · 2023: $966 · 2024: $1,573 · 2025: $2,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,729 · Education: $64.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,728.51 |
| Education | $64.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,848.01 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $797.71 | 2022-2025 | Airsupra, Tezspire, Breztri |
| Grifols USA, LLC | $658.82 | 2022-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $528.17 | 2023-2025 | Sunosi |
| Mylan Specialty L.P. | $373.33 | 2021-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.25 | 2021-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $344.13 | 2024-2025 | Dupixent |
| Genzyme Corporation | $287.31 | 2024-2025 | |
| Harmony Biosciences LLC | $225.59 | 2024-2025 | |
| Insmed, INC. | $160.11 | 2021-2025 | Arikayce, Brinsupri |
| Amgen INC. | $148.33 | 2024-2025 | Tezspire |
| Inspire Medical Systems, INC. | $144.44 | 2023-2025 | Inspire |
| Inogen, INC. | $35.12 | 2022 | |
| Lilly USA, LLC | $24.23 | 2025 | Zepbound |
| Viatris Specialty LLC | $23.99 | 2025 | Yupelri |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.72 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Grimes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.